Uncategorized

Amylin – Byetta off to a strong start

This afternoon Amylin Pharmaceuticals (NASDAQ:AMLN) announced their second quarter results. Prior to release of the numbers Diabetic Investor felt that Amylin was in a no win situation as no matter what the results were they would not meet Street expectations. Earlier in the day Smith Barnet downgraded Amylin from a buy to sell rating. The main reason given for the downgrade was slower physician acceptance of Byetta. Not surprisingly Amylin...

Animas – Why the numbers don’t add up

After listening to the Animas (NASDAQ:PUMP) second quarter conference call one might come away with the impression that the future looks brighter than the past. The company reported solid results, raised revenue estimates and from all appearances has a solid pipeline of new products for the future. Taking a closer look at all the numbers tells a different story. 1. 1. For the six months...

AMLN – Is this pullback a buying opportunity

Welcome to the roller-coaster ride for shareholders of Amylin Pharmaceuticals (NASDAQ:AMLN). Just a few months ago shares of Amylin were trading in the low teens, closing at $14.65 back on June 8th. Fast forward to July 20th when shares closed at $22.04, that’s a 50% gain in just over a month’s time. Is it any wonder that investors have been taking profits and that shares are now trading just above...

Exubera, A step closer

Yesterday shares of Nektar Therapeutics (NASDAQ:NKTR) rose 3% on news that FDA has scheduled a panel meeting for September 8th, to discuss Exubera. (Exubera is a form of inhaled insulin.) Partnered with Nektar on Exubera are drug giants Pfizer (NYSE:PFE) and Sanofi-Aventis (NYSE:SNY). While it is encouraging that the FDA has set a panel meeting this does not mean that approval is a forgone conclusion. Exubera has a long...

Pump Report

Finally the pump report has made it to the printer, this is no small accomplishment considering last Thursday there was a fire at my home. While this did delay the report getting to the printer as I had some other issues to deal with, the report will be ready shortly. If you have not yet ordered your copy of the report there is still time. You can contact us...

Pump Report Update/ADA

There is still time to order our special report on the insulin pump market. The report is currently going through the final editing process and should be at the printer early next week. If all goes well the report will be ready for shipment late next week. Anyone who has ordered the report and has special shipping instructions please contact Diabetic Investor at dkliff@diabeticinvestor.com. Anyone interested in purchasing report...

Roche Update

Yesterday I had the pleasure of attending Roche Diagnostics investor’s day. First the good news, the new Aviva blood glucose meter looks like a winner. Designed to replace the aging Advantage meter, the Aviva will put Roche on equal footing with the OneTouch Ultra from LifeScan (LifeScan is a unit of Johnson and Johnson NYSE:JNJ) and FreeStyle (FreeStyle made by Therasense which is part of Abbott NYSE:ABT) meters. Like the...

Out of Control

Two-thirds of the nation’s 18 million Type 2 diabetics don’t have their blood sugar under control. That was the conclusion of a report released at the American Association of Clinical Endocrinologist (AACE) meeting. Making matters even worse the report also concluded that most patients were unaware they were doing so poorly. The American Diabetes Association (ADA) defines good control as a patient with an A1C level of 7%...

Animas Reports

Yesterday insulin pump maker Animas (NASDAQ:PUMP) reported solid first quarter revenues of $19.3 million an increase of 67% from adjusted net revenues for first quarter 2004. Although the company has run into a series of unfortunate events, product recall and warning letter, sales appear to be accelerating. In particular international revenues represent 18% of total revenue compared to just 8% a year ago. The real story behind them numbers...

Why the Street is Wrong on Amylin

The strangest thing happened on Friday, a new drug with blockbuster potential gets approved and the stock of the company that discovered the drug went down. Stranger still is all the explanations given for why the stock went down. The fact of the matter is the street is dead wrong on Amylin (NASDAQ:AMLN) and this is buying opportunity if there ever was one. After reviewing the comments made...